Table 3.
Standardized incidence rates with 95% CIs for 2020 and 2021 compared to 2019 for different tumors according to ICD-O-3.2 topography.
| Tumor Topography | N 2020 | SIR 2020 | 95% CI 2020 | N 2021 | SIR 2021 | 95% CI 2021 |
|---|---|---|---|---|---|---|
| Lip, oral cavity, pharynx (C00–C14) | 677 | 92.3 | 85.5–99.4 | 728 | 98.5 | 91.5–105.8 |
| Esophagus (C15) | 210 | 96.7 | 84.1–110.2 | 238 | 108.6 | 95.3–122.9 |
| Stomach (C16) | 684 | 80.2 | 74.3–86.4 | 868 | 101.3 | 94.7–108.1 |
| Colon, rectum (C18–C20) | 3628 | 74.9 | 72.5–77.3 | 4288 | 87.8 | 85.2–90.4 |
| Pancreas (C25) | 780 | 98.1 | 91.4–105.1 | 872 | 108.8 | 101.7–116.1 |
| Other digestive tract (C17, C21, C26) | 230 | 90.6 | 79.3–102.7 | 249 | 971 | 85.9–110.1 |
| Larynx (C32) | 312 | 95.5 | 85.2–160.4 | 350 | 106 | 95.2–117.4 |
| Lung (C34) | 2866 | 92.3 | 89–95.7 | 3199 | 102.1 | 98.6–105.7 |
| Thymus, heart, mediastinum (C37-C39) | 100 | 84.6 | 68.8–102 | 103 | 86.7 | 70.7–104.2 |
| Nasopharynx (C31, C31, C33) | 52 | 85.2 | 63.2–109.9 | 52 | 84.6 | 63.2–109.2 |
| Bones (C40–C41) | 62 | 62.5 | 47.9–79 | 71 | 71.4 | 55.7–88.9 |
| Skin (C44) | 1043 | 83.1 | 78.1–88.2 | 1360 | 108.1 | 102.4–113.9 |
| Retroperitoneum, peritoneum (C48–C49) | 225 | 96.7 | 84.5–109.8 | 292 | 125.2 | 111.3–140 |
| Breast (C50) | 3859 | 93 | 90.1–96 | 4775 | 114.4 | 111.2–117.7 |
| Vulva, vagina (C51–C52) | 127 | 130 | 108.4–153.6 | 127 | 129.4 | 107.9–152.9 |
| Cervix (C53) | 240 | 99.1 | 87–112.1 | 273 | 113 | 100–126.9 |
| Endometrium (C54) | 599 | 93.7 | 86.4–101.4 | 622 | 96.5 | 89–104.2 |
| Ovary (C56) * | 326 | 82.5 | 73.8–91.7 | 402 | 100.9 | 91.3–111 |
| Uterus non specified (C55, C57, C58) | 41 | 115.3 | 82.7–153.3 | 47 | 131.4 | 96.5–171.7 |
| Prostate (C61) | 2895 | 75.1 | 72.4–77.8 | 3411 | 87.8 | 84.9–90.8 |
| Testis (C62) | 131 | 99.8 | 83.4–117.6 | 134 | 103.8 | 87–122.1 |
| Penis (C60–C63) | 47 | 73.5 | 54–96 | 52 | 81.1 | 60.6–104.7 |
| Kidney, urinary tract (C64, C66–C68) | 2693 | 82.9 | 79.8–86.1 | 2986 | 91.4 | 88.1–94.7 |
| Renal pelvis (C65) | 60 | 96.5 | 73.6–122.4 | 87 | 138.6 | 111–169.3 |
| Eye (C69) | 63 | 97.6 | 75–123.1 | 52 | 80.3 | 60–103.6 |
| Meninges, brain, spinal cord (C70–C72) | 611 | 89.8 | 82.8–97 | 663 | 97.1 | 89.8–104.6 |
| Thyroid (C73) | 640 | 76.8 | 71–82.99 | 726 | 87.1 | 80.9–93.6 |
| Adrenal gland, other endocrine (C74, C75) | 78 | 62 | 49–76.6 | 102 | 81.1 | 66.2–97.7 |
| Unknown primary site (C80) | 334 | 112.4 | 100.7–124.8 | 326 | 109 | 97.5–121.1 |
| Lymphoid, myeloid (C42, C77) | 2666 | 93.3 | 89.8–96.9 | 2833 | 98.7 | 95.1–102.4 |
SIR (95% CI): standardized incidence ratio (95% confidence interval); 95% CIs including 1 are not statistically significant; SIRs below 1 indicate significant underdiagnosis (in orange color), and over 1 indicate significant overdiagnosis (in green color). * In situ carcinoma was excluded from the analysis as it was not registered until 2020.